SCHEMBL1483068

SCHEMBL1483068

N#Cc1ccc(C#Cc2cc(Cl)ccc2-c2nc3ccccc3n2CC2CCCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.44
PRKACA P17612 2/20 0.41
RPS6KB1 P23443 2/20 0.41
GSK3B P49841 2/20 0.41
ROCK1 Q13464 2/20 0.41
DRD2 P14416 1/20 0.40
TBXA2R P21731 1/20 0.40
CNR2 P34972 2/20 0.39
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PDE6D O43924 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
BRD4 O60885 1/20 0.37
KDM1A O60341 2/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482700 0.89 PRKACA (0.44) PRKACARPS6KB1GSK3BROCK1CNR2
SCHEMBL1483118 0.88 NR1H4 (0.47) ALOX5CNR2CTSLCTSSCTSK
SCHEMBL1482352 0.84 ALOX5 (0.43) ALOX5PRKACARPS6KB1GSK3BROCK1
SCHEMBL1482589 0.79 PRKACA (0.42) PRKACARPS6KB1GSK3BROCK1KDM4E
SCHEMBL1482134 0.79 RXRA (0.43) CNR2CTSSNPSR1NR1H4BRD4
SCHEMBL1482462 0.79 ALOX5 (0.53) ALOX5PRKACARPS6KB1GSK3BROCK1
SCHEMBL1482478 0.79 CNR2 (0.40) ALOX5CNR2NPSR1NR1H4KCNH2
SCHEMBL1482155 0.78 ALOX5 (0.52) ALOX5PRKACARPS6KB1GSK3BROCK1
SCHEMBL1483150 0.78 PRKACA (0.39) PRKACARPS6KB1GSK3BROCK1DRD2
SCHEMBL1482337 0.78 GLP1R (0.40) ALOX5PRKACARPS6KB1GSK3BROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 ALOX5 3919/4885PRKACA 2884/4885RPS6KB1 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.